Last reviewed · How we verify

Bupivicaine alone — Competitive Intelligence Brief

Bupivicaine alone (Bupivicaine alone) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic. Area: Anesthesia.

phase 3 Local anesthetic Voltage-gated sodium channels Anesthesia Small molecule Live · refreshed every 30 min

Target snapshot

Bupivicaine alone (Bupivicaine alone) — The Cleveland Clinic. Bupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of nerve impulses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Bupivicaine alone TARGET Bupivicaine alone The Cleveland Clinic phase 3 Local anesthetic Voltage-gated sodium channels
Control (bupivacaine) Control (bupivacaine) Kasr El Aini Hospital marketed Local anesthetic (amide) Voltage-gated sodium channels
Bupivacaine Liposomes(BL) Bupivacaine Liposomes(BL) Huazhong University of Science and Technology marketed Local anesthetic (liposomal formulation) Voltage-gated sodium channels
Remifentanil+Lidocaine Remifentanil+Lidocaine The First Affiliated Hospital of Zhengzhou University marketed Opioid analgesic + Local anesthetic combination Mu-opioid receptor (remifentanil); Voltage-gated sodium channels (lidocaine)
Bupivacaine-fentanyl elective group Bupivacaine-fentanyl elective group Conrad Arnfinn Bjørshol marketed Local anesthetic with opioid analgesic combination Voltage-gated sodium channels (bupivacaine); mu opioid receptor (fentanyl)
ropivacaine and ketorolac ropivacaine and ketorolac University of Aarhus marketed Local anesthetic + NSAID combination Voltage-gated sodium channels (ropivacaine); COX-1 and COX-2 (ketorolac)
Marcaine Injectable Product Marcaine Injectable Product University of California, Davis marketed Local anesthetic Voltage-gated sodium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic class)

  1. University of California, San Diego · 3 drugs in this class
  2. Durect · 3 drugs in this class
  3. Pacira Pharmaceuticals, Inc · 3 drugs in this class
  4. Wake Forest University Health Sciences · 3 drugs in this class
  5. Medical University of Vienna · 3 drugs in this class
  6. Imperial College London · 2 drugs in this class
  7. Hvidovre University Hospital · 2 drugs in this class
  8. Innocoll · 2 drugs in this class
  9. George Washington University · 2 drugs in this class
  10. Guy's and St Thomas' NHS Foundation Trust · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Bupivicaine alone — Competitive Intelligence Brief. https://druglandscape.com/ci/bupivicaine-alone. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: